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Abstract
Background: Relapse in localized Ewing sarcoma patients has been a matter of concern regarding poor prognosis.
Therefore, we investigated the impact of local control modality (surgery, surgery plus radiotherapy, and
radiotherapy) on clinical outcomes such as survival and recurrence in patients with non-metastatic Ewing sarcoma
treated on the first Brazilian Collaborative Group Trial of the Ewing Family of Tumors (EWING1).
Methods: Seventy-three patients with localized Ewing sarcoma of bone aged < 30 years were included. The
treating physicians defined the modality of local control based on the recommendations of the coordinating center
and the patient and tumor characteristics. Possible associations of local control modality with local failure (LF),
disease-free survival (DFS), event-free survival (EFS), overall survival (OS), and clinical characteristics were analyzed.
Results: Mean patient age was 12.8 years (range, 2 to 25 years) and median follow-up time was 4.5 years (range, 2.
3 to 6.7 years). Forty-seven patients underwent surgery, 13 received radiotherapy, and 13 received both. The 5-year
EFS, OS, and DFS for all patients was 62.1%, 63.3%, and 73.1%, respectively. The 5-year cumulative incidence (CI) of
LF was 7.6% for surgery, 11.1% for radiotherapy, and 0% for postoperative radiotherapy (PORT) (p = 0.61). The 5-year
EFS was 71.7% for surgery, 30.8% for radiotherapy, and 64.1% for PORT (p = 0.009).
Conclusions: There was a significant effect of local control modality on EFS and OS in the study. Surgery and PORT
modalities yielded very close results. The group treated with radiotherapy alone had considerably worse outcomes.
This may be confounded by greater risk factors in these patients. There was no significant effect of local control
modality on the CI of LF and DFS.
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Background
Ewing sarcoma (ES) is a small round cell malignancy of
bone and soft tissue that usually occurs in individuals
aged 5 to 20 years. Five-year overall survival (OS) for
patients with localized disease ranges from 65 to 75%,
while disease relapse after local control reduces survival
to less than 25% [1–8]. Multicenter trials have demon-
strated the importance of aggressive chemotherapy treat-
ment and local control of the primary tumor. Successful
local control rates have improved to 74–93% with the
introduction of a multidisciplinary and collaborative
approach [9–12].
Current ES treatment includes induction chemother-
apy, local control of the primary tumor, and consolida-
tion chemotherapy. Surgery alone or in combination
with radiation has traditionally been considered a good
choice for resectable ES, while most unresectable tumors
have been treated with radiation alone. However, recent
studies have reported worse local recurrence and sur-
vival rates in patients treated with radiotherapy alone
compared to surgery and postoperative radiotherapy
(PORT). These findings have been associated with risk
factors that are present in irradiated patients [12–19].
For the first time in Brazil, data on local control of ES
were analyzed within a single multicenter protocol. We
used a cohort of patients with localized ES treated on the
EWING1 trial (first Brazilian Collaborative Group Trial
for treatment of Ewing sarcoma family of tumors [ESFT])
[20] to evaluate different local control strategies and their
association with risk factors, relapse, and survival.
Methods
Patient enrollment
The study was approved by the institutional review board
of Hospital de Clínicas de Porto Alegre through the Office
of Research and Graduate Studies (IRB No. 00000921). All
patients signed an informed consent form prior to their
inclusion in the EWING1 trial from 2003 to 2010 (original
trial, IRB No. 03363, date: October 15, 2003).
Patients with localized ES of bone treated between 2003
and 2010 according to the EWING1 trial were eligible for
the study. Patients were allocated to low-risk (LRG) or
high-risk (HRG) groups, where high-risk patients were de-
fined as those with unresectable tumors, tumors of the
pelvis, and lactate dehydrogenase (LDH) levels ≥ 1.5 times
the upper limit of normal (x ULN). Tumor size was
assessed on magnetic resonance imaging (MRI) and com-
puted tomography (CT) scans before starting induction
chemotherapy and categorized into ≤ 8 cm (small tumors)
and > 8 cm (large tumors). Chemotherapy response was
defined as good or poor according to the necrosis index
(> 95% or ≤ 95%, respectively) [21, 22].
Patients were treated at 15 centers located in 6 states in
Brazil, and one in Uruguay. Each center’s institutional review
board approved the treatment protocols, and written in-
formed consent was obtained for all patients at enrollment.
Treatment
In the EWING1 trial, the induction chemotherapy con-
sisted of two courses of ifosfamide/carboplatin/etoposide
(ICE) and two courses of vincristine/doxorubicin/cyclo-
phosphamide (VDC), followed by local control. After local
treatment, LRG patients received 10 additional alternating
cycles of ifosfamide/etoposide (IE) with VDC, while HRG
patients received two additional cycles of ICE at the end of
the consolidation therapy. Details of the treatment plan
and timing of local control have been published previously
[20].
Local control modality was defined based on the ex-
perience of treating physicians within each participating
institution; however, the coordinating center established
some criteria based on the patient and tumor character-
istics to standardize the choice of local control. Patients
with tumors that were amenable to resection with ad-
equate margins, regardless of size, response to chemo-
therapy, or location, should be treated surgically. Cases
with positive surgical margins, in which wide resection
was not possible due to high morbidity, should receive
PORT. The dose of PORT was defined as 45 Gy for mar-
ginal resections and 55.8 Gy for intralesional resections.
The presence of necrotic tissue, even in the absence of
viable ES cells, was considered incomplete resection and
treated with 55.8 Gy. Patients with tumors of the ribs,
with a pleural effusion contiguous to a primary lesion,
should also receive PORT.
Definitive radiation was given to patients when wide
resection could cause high morbidity or mutilation, and in
unresectable tumors. Radiation was planned according to
the X-ray, CT, and MRI when available. Radiotherapy was
delivered to the original tumor volume with a 2-cm
margin and a total dose of 55.8 Gy at 1.8 Gy/fraction
started during week 11. At the end of treatment, it was
established that patients would be followed up every
3 months during the first 2 years, then every 6 months for
5 years, and annually thereafter.
Recurrence was classified as local or systemic. For ana-
lysis purposes, any local recurrence was defined as local
failure (LF) and systemic recurrence as distant failure
(DF). Combined recurrences were included in the
systemic group. The classification of the local control
modality received by each patient was determined accord-
ing to all interventions performed at the local tumor site
up to and including the start of consolidation therapy.
Local control was classified into one of three procedures:
surgery, radiotherapy, or surgery plus radiotherapy. Over-
all survival (OS), event-free survival (EFS), and disease-
free survival (DFS) were defined as the time from the end
of all local control measures until a respective event
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occurs or last patient contact, at which time the patient
was censored. Patients who experienced disease progres-
sion, second malignant neoplasm, or death were scored as
having experienced an event.
Statistics
The outcome measures were OS, EFS, DFS, and cumulative
incidence (CI) of LF and DF timed from the completion of
local control therapy, as calculated by the Kaplan-Meier
method. The CI of each type of event was calculated for
each method of local control and compared by the log-rank
test. Associations between categorical variables were ana-
lyzed using Pearson’s chi-square test. The Mann-Whitney
test was used to compare medians for radiation dose. The
association between local control modality and event risk
was analyzed using univariate and multivariate Cox
proportional-hazards regression models. The hazard ratio
(HR) and 95% confidence interval (95% CI) were used as
the measure of effect.
Results
Patients selection and characteristics
Data from 73 patients (45 males and 28 females, mean age
of 12.8 years) with localized bone disease submitted to
local control were selected from a total of 175 patients (96
with localized bone and extraosseous ES and 79 with
metastatic bone and extraosseous ES) of the EWING1
trial. The median follow-up time of patients in this study
was 4.5 years (range, 2.3 to 6.7 years). Forty-three tumors
(58.9%) were located in the extremities, 10 (13.7%) in the
pelvis, 10 (13.7%) in the chest wall, 6 (8.2%) in the spine,
and 4 (5.5%) in other sites (p > 0.001). Thirty-eight
(52.1%) patients were allocated as LRG and 35 (47.9%) pa-
tients as HRG (p < 0.001). Pelvic tumors were relatively
more likely to receive radiotherapy than surgery alone. On
the other hand, non-pelvic tumors were more frequently
treated with surgery (p = 0.012). Tumor size ≤ 8 cm
vs > 8 cm was not significantly associated with the local
control modality performed (p = 0.12). The response to
chemotherapy was poor (necrosis index ≤ 95%) in 56%
and good (> 95%) in 44% of patients. Of 68 patients with
complete LDH records, only 15 (22%) had LDH ≥ 1.5 x
ULN and were more likely to have a surgical procedure
(66.6%) than radiotherapy alone (33.3%) (p = 0.05). The
median radiation dose was 50.4 Gy for both groups (range,
45.0 to 55.9 Gy).
Of 43 patients with tumors of the extremities, almost
all underwent surgical treatment (n = 41, 95.4%), while
only 2 (4.6%) received radiotherapy alone. Of 16 patients
with tumors of the pelvis and spine, only 6 (37.5%)
underwent surgery, while 10 (62.5%) received radiother-
apy alone (p < 0.001) (Table 1).
Overall analysis
The estimated 5-year EFS, OS, and DFS for all 73 patients
was 62.1%, 63.3%, and 73.1%, respectively. The 5-year CI
of LF and DF was 6.9% and 14.7%, respectively. Sixty-eight
patients had complete information on local or distant
recurrence. Only 4 had isolated LF, and 11 had DF
combined or not with LF (Table 2; Figs. 1, 2, and 3).
The 5-year EFS was not statistically different according
to tumor size ≤ 8 cm vs > 8 cm at presentation (61.1% vs
58.1%, HR = 1.07; P = 0.89), pelvic location (41.1% vs
66.7%, HR = 1.47; p = 0.44), LDH levels < 1.5 vs ≥ 1.5 x
ULN (63.1% vs 51.3%, HR = 1.11; p = 0.83), or radiation
dose (HR = 0.99; p = 0.56). LRG and HRG patients had
EFS rates of 73.7% and 48.2% and LF rates of 5.6% and
8.3%, respectively (p = 0.16) (Table 2).
On multivariate analysis, definitive radiotherapy,
age > 15 years and HRG were not associated with a higher
risk of any event (Table 3).
Local control analysis
The 5-year EFS was 30.8% for patients submitted to de-
finitive radiotherapy (13 patients), 64.1% for surgery plus
radiotherapy (13 patients), and 71.7% for surgery alone
(47 patients) (p = 0.009). There was no significant differ-
ence in LF rates by local control modality (p = 0.61), and
the LF rates were the same at 2 and 5 years of follow-up:
7.6% in the surgery group, 11% in the radiotherapy
group, and 0% in the PORT group (p = 0.62). Consider-
ing all 15 patients with local or systemic recurrence, the
CI of LF and DF at both 2 and 5 years was 11% for
radiotherapy alone, 16.7% for surgery plus radiotherapy,
and 25% for surgery alone (p = 0.64). The local disease
control rate was 78%.
Discussion
Small round cells tumors such as ES are usually good
responders to irradiation. Consequently, radiotherapy has
been an important option for local control either alone or
with surgery. However, radiotherapy is not free from
complications at the primary tumor sites. Soft tissue fibro-
sis, osteonecrosis, impaired long-bone growth, secondary
malignancies, and up to 35% rate of local recurrence have
been related to high-dose irradiation [5, 9–13, 23].
On the other hand, development of orthopedic endo-
prostheses has enabled surgeons to perform non-mutilating
procedures with adequate margins in ES patients. Continu-
ous advances have introduced structural auto and allografts
in surgical reconstructions, thus offering more biological
treatment options. Therefore, amputation has become
extremely infrequent in ES [24, 25].
The presence of marginal or contaminated margins is
still the main indication for PORT in the treatment of ES.
Conversely, PORT has been routinely used in patients
with poor response to chemotherapy as well as in large-
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volume tumors in European centers. The current consen-
sus on the type of local treatment of ES follows criteria
based on the patient and tumor characteristics and, not
less important, on the level of experience of treating physi-
cians [12–19].
The heterogeneity of clinical factors may be a source of
confusion when following the guidelines for local treatment
in ES [6, 26]. Yock et al. evaluated the impact of the local
control modality for localized ES in a non-randomized
study including 75 patients with pelvic bone disease. There
was no difference in recurrence rates or survival between
the different local control methods. However, patients with
larger tumors were more likely to receive combined surgery
plus radiotherapy (p = 0.013) [19]. Similarly, in the
EWING1 trial, there was no difference in recurrence rate
(LF) between the different treatment modalities, and larger
tumors were more likely to receive surgery and PORT than
radiotherapy (p = 0.12). Nevertheless, we believe that the
limited size of the sample and the inability to control for
confounding factors may be reflected in the results.
Table 1 Characteristics of the Sample according to the Local Control Modality
Variables Total sample Local Control Modality p
Surgery Surgery + Radiotherapy Radiotherapy
n (%) n (%) n (%) n (%)
All patients 73 (100) 47 (64.4) 13 (17.8) 13 (17.8)
Age group 0.753
≤ 15 years 51 (69.9) 34 (72.3) 8 (61.5) 9 (69.2)
> 15 years 22 (30.1) 13 (27.7) 5 (38.5) 4 (30.8)
Sex 0.035
Male 45 (61.6) 33 (70.2)a 4 (30.8) 8 (61.5)
Female 28 (38.4) 14 (29.8) 9 (69.2)a 5 (38.5)
Risk group <0.001
Low 38 (52.1) 33 (70.2)a 5 (38.5) 0 (0.0)
High 35 (47.9) 14 (29.8) 8 (61.5) 13 (100)a
Tumor size 0.124
≤ 8 cm 18/45 (40.0) 10/31 (32.3) 4/9 (44.4) 4/5 (80.0)
> 8 cm 27/45 (60.0) 21/31 (67.7) 5/9 (55.6) 1/5 (20.0)
Necrosis Index 1.000
≤ 95% 28/50 (56.0) 23/42 (54.8) 5/8 (62.5) NA
> 95% 22/50 (44.0) 19/42 (45.2) 3/8 (37.5) NA
LDH 0.052
≥ 1.5 x ULN 15/68 (22.1) 6/45 (13.3) 4/10 (40.0) 5/13 (38.5)
< 1.5 x ULN 53/68 (77.9) 39/45 (86.7) 6/10 (60.0) 8/13 (61.5)
Recurrence 0.509
No 53/68 (77.9) 34/46 (73.9) 10/12 (83.3) 9/10 (90.0)
Local 4/68 (5.9) 3/46 (6.5) 0/12 (0.0) 1/10 (10.0)
Systemic 11/68 (16.2) 9/46 (19.6) 2/12 (16.7) 0/10 (0.0)
Site location <0.001
Spine 6 (8.2) 0 (0.0) 1 (7.7) 5 (38.5)a
Chest wall 10 (13.7) 6 (12.8) 4 (30.8)a 0 (0.0)
Pelvis 10 (13.7) 3 (6.4) 2 (15.4) 5 (38.5)a
Proximal extremity 21 (28.8) 17 (36.2)a 2 (15.4) 2 (15.4)
Distal extremity 22 (30.1) 19 (40.4)a 3 (23.1) 0 (0.0)
Other 4 (5.5) 2 (4.3) 1 (7.7) 1 (7.7)
Radiation dose (Gy)b 50.4 (45–55.8) NA 50.4 (45–54.9) 50.4 (45–55.8) 0.801
aStatistically significant association by adjusted residual analysis at 5% significance level
bExpressed as median (25th–75th percentile)
LDH lactate dehydrogenase, NA not applicable, ULN upper limit of normal
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Surgery is reserved for situations in which the tumor
can be resected with adequate margins, that is, with no
evidence of residual disease. Although based on observa-
tional studies, local recurrence and survival have shown
better results in patients submitted to neoadjuvant
chemotherapy and surgery compared to patients submit-
ted to neoadjuvant chemotherapy and radiotherapy [16,
27, 28]. DuBois et al. analyzed using propensity scores
the risk of LF and survival in 465 patients with localized
ES of bone and found that radiotherapy had a higher
risk of local recurrence and death than surgery alone
[13]. In the EWING1 trial, radiation therapy showed
worse results in terms of EFS (p = 0.009) than surgery
and PORT. These findings should be analyzed with
caution because 70% (9/13) of the patients subjected to
radiation had unresectable tumors; 10 patients had
tumors located in the spine and pelvis and 3 developed
secondary myeloproliferative neoplasms at the beginning
of the follow-up period. Due to the small number of
local recurrences (n = 4), there was no significant differ-
ence in LF rates by local control modality.
Several studies included only patients with pelvic ES to
investigate possible associations between local control
modality and treatment failure [19, 29–31]. Raciborska et
al. found that survival was higher in patients treated with
surgery and PORT than in those treated with radiotherapy
alone (81% and 78% vs 36% at 3 years, respectively) [29].
In the present study, 10 patients had pelvic tumors, and
50% of these patients were treated with definitive radio-
therapy (p = 0.012). As expected, survival was consider-
ably lower in patients with pelvic compared to non-pelvic
tumors (41.1% vs 66.7%, p = 0.44). There was no differ-
ence in the incidence of LF and survival between the dif-
ferent local control measures in the pelvis.
Nowadays, definitive radiation is an almost exclusive indi-
cation for unresectable tumors and for patients with poorer
prognosis for whom surgical procedures may be exception-
ally mutilating. Advances in radiation technology and
multidisciplinary approach have enhanced local control and
decreased complications in healthy tissues surrounding
tumors. Studies analyzing the use of radiation alone re-
ported 5-year local control rates ranging from 53 to 86%
Table 2 Results of univariate analysis for possible independent variables associated with death and EFS
Variables EFS LF
5-year CI HR (95% CI) p 5-year CI HR (95% CI) p
All patients 62.1% - - 6.9% - -
Age group
≤ 15 years 68.0% 1.00 4.6% 1.00
> 15 years 47.6% 2.00 (0.91–4.41) 0.087 13.8% 3.11 (0.44–22.1) 0.257
Sex
Male 64.0% 1.00 9.1% 1.00
Female 58.6% 1.30 (0.60–2.83) 0.513 4.8% 0.58 (0.06–5.53) 0.575
Risk group
Low 73.7% 1.00 5.6% 1.00
High 48.2% 1.74 (0.80–3.80) 0.163 8.3% 1.33 (0.19–9.41) 0.779
Tumor size
≤ 8 cm 61.1% 1.00 – – –
> 8 cm 58.1% 1.07 (0.41–2.76) 0.892 – – –
Necrosis Index
≤ 95% 60.7% 1.38 (0.54–3.57) 0.503 5.6% 0.41 (0.04–4.52) 0.466
> 95% 71.3% 1.00 10.5% 1.00
LDH
≥ 1.5 x ULN 51.3% 1.11 (0.44–2.77) 0.832 15.4% 6.04 (0.55–66.7) 0.142
< 1.5 x ULN 63.1% 1.00 2.4% 1.00
Pelvic location
Yes 41.1% 1.47 (0.55–3.90) 0.440 – – –
No 66.7% 1.00 – – –
Radiation dose - 0.99 (0.98–1.01) 0.560 - 0.98 (0.86–1.12) 0.796
EFS event-free survival, LF local failure, CI cumulative incidence, HR hazard ratio; 95% CI, 95% confidence interval, LDH lactate dehydrogenase, ULN upper limit
of normal
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with doses between 45 and 65 Gy [9–11, 26, 32, 33]. The
EWING1 trial demonstrated that most patients with
unresectable tumors and tumors located in the spine and
pelvis were treated with definitive radiotherapy. Consider-
ably worse results were obtained in patients treated with
radiotherapy alone than in those treated with surgery and
PORT. This may be due to high disease morbidity, subopti-
mal local control with radiotherapy alone, or a combination
of these and other factors. The differing clinical charac-
teristics of the radiotherapy group precluded a perfectly
reliable comparison between the different local treatment
modalities.
Moreover, EWING1’s sample was characterized by pa-
tients with many risk factors associated with poor prog-
nosis. Forty-eight percent were in the HRG, and more
than half had tumors >8 cm and were poorer responders
Fig. 2 Overall survival according to the local treatment modality
Fig. 1 Event-free survival according to the local treatment modality
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to chemotherapy. These worse characteristics suggest a
delay in ES diagnosis probably related to social and
economic issues from a developing country. Furthermore,
higher resistance to chemotherapy could be related to
both larger tumors and a specific resistance profile of the
patients. Despite all this, for 73 patients included in the
current study, the remission rate was 78%.
In summary, we observed similar results to those
published by large international cooperative groups [5, 16,
19, 34]. Every effort made to provide training to local in-
vestigators, gather data, and monitor the progress of the
first Brazilian protocol for ES has allowed us to describe
the different local control strategies used in the treatment
of ES in a country of continental size like Brazil. The great
Table 3 Results of multivariate analysis for independent variables associated with death and EFS
EFS p LF p
Variables HR (95% CI) HR (95% CI)
Type of treatment
Surgery 1.00 1.00
Surgery + Radiotherapy 0.88 (0.28–2.74) 0.829 * *
Radiotherapy 1.84 (0.63–5.41) 0.267 1.01 (0.08–12.8) 0.991
Age group -
≤ 15 years 1.00 -
> 15 years 2.12 (0.96–4.71) 0.064 -
Risk group -
Low 1.00 -
High 1.41 (0.53–3.71) 0.489 -
LDH
≥ 1.5 x ULN - 6.28 (0.50–79.1) 0.155
< 1.5 x ULN - 1.00
*It is not possible to estimate risk because the interval tends to infinity
EFS event-free survival, LF local failure, HR hazard ratio, 95% CI, 95% confidence interval, LDH lactate dehydrogenase, ULN upper limit of normal
Fig. 3 Cumulative incidence of isolated local recurrence in relation to local treatment modality
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economic, cultural and social diversity of patients as well
as the different levels of knowledge of health professionals
on the topic make clear the importance of a collaborative
approach for a study of this magnitude.
Conclusion
The EWING1 trial found no significant difference in
local or systemic disease recurrence between different
treatment modalities. However, regarding survival, there
was a significant difference between surgery, radiother-
apy, and PORT.
The Brazilian Collaborative Study Group for treat-
ment of ESFT has now been incorporated into the
newly formed Latin American Pediatric Oncology
Group (GALOP) and a second ESFT study was acti-
vated in 2011 [28]. The next step is intended to
analyze and report the impact of local control in the
second ESFT study.
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